Daewoong Pharmaceutical posts strong financials in 2021
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Launching in 2022, its availability will be expanded to the global market
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Subscribe To Our Newsletter & Stay Updated